Loading...
India's zinc imports from POLAND total $10 across 1 shipments from 1 foreign suppliers. Roland Karlinski leads with $10 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include MEDICEPT DENTAL INDIA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for zinc — a concentrated sourcing relationship with select suppliers from POLAND.
Roland Karlinski is the leading Zinc supplier from POLAND to India, with import value of $10 across 1 shipments. The top 5 suppliers — Roland Karlinski — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | Roland Karlinski | $10 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MEDICEPT DENTAL INDIA PRIVATE LIMITED | $10 | 1 | 100.0% |
POLAND → India trade corridor intelligence
As of April 2026, the Poland to India trade corridor for pharmaceutical imports, including finished zinc formulations, is operating efficiently. Sea freight from Poland to India typically takes around 30 days, while air freight is approximately 7 days. The majority of shipments are transported by sea (80%), with a smaller portion by air (20%). There are no significant port congestions reported at major Indian ports such as Jawaharlal Nehru Port (JNPT), Chennai, or Mundra. Freight rates have remained stable, and the exchange rate between the Indian Rupee (INR) and the Polish Zloty (PLN) has not experienced significant fluctuations.
The Indian government's Production-Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, has impacted the import of finished formulations, including those containing zinc. While the PLI scheme aims to reduce import dependency by encouraging domestic production, it has also led to increased scrutiny and regulatory requirements for imported products. Import substitution policies are being implemented to promote self-reliance, which may affect the volume of finished formulation imports from countries like Poland.
India and Poland maintain a cordial trade relationship, with ongoing discussions to enhance bilateral trade, including in the pharmaceutical sector. There are no specific Free Trade Agreements (FTAs) between the two countries; however, both nations are members of the World Trade Organization (WTO), which facilitates trade negotiations and dispute resolutions. Efforts are being made to recognize each other's Good Manufacturing Practice (GMP) certifications, which would streamline the import process for pharmaceutical products.
For a shipment of finished zinc formulations from Poland to India, the estimated landed cost per unit is calculated as follows:
CDSCO registration, import licensing, and quality testing requirements
As of April 2025, the Central Drugs Standard Control Organization (CDSCO) mandates that all pharmaceutical imports into India, including finished formulations containing zinc, require an import license. This license is issued after evaluating the product's safety, efficacy, and quality data. The Drug Controller General of India (DCGI) oversees this process. Additionally, an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) is necessary for customs clearance. The registration process involves submitting Form 40/41, along with supporting documents such as a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining the import license can vary but typically ranges from 3 to 6 months, depending on the completeness of the application and the regulatory review process.
Imported finished pharmaceutical formulations containing zinc must undergo quality testing at CDSCO-approved laboratories in India. This includes batch-wise testing to ensure compliance with the Indian Pharmacopoeia standards. A Certificate of Analysis (CoA) is required for each batch, along with stability data demonstrating compliance with International Council for Harmonisation (ICH) Zone IV conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the products. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or additional costs for the importer.
Between 2024 and 2026, the Indian government introduced stricter regulations for imported medicines to prevent the sale of unapproved or illegal products. As of April 2025, import registration and licenses have been made mandatory by the CDSCO for all pharmaceutical imports, including finished formulations containing zinc. This policy aims to streamline the procedure for transferring drugs manufactured in Special Economic Zones (SEZs) to the Domestic Tariff Area (DTA) for sale and distribution, ensuring that imported drugs meet quality, safety, and efficacy standards. The policy also prohibits the transfer of banned drugs manufactured in SEZs to the DTA.
Market demand, customs duty structure, and competitive landscape · Import duty: 17.10%
India imports finished zinc formulations primarily due to the demand for patented or branded products, specific dosage forms not available domestically, and to meet therapeutic needs that domestic manufacturers cannot fulfill. The market size for zinc formulations in India is substantial, with a total export market of $79.2 million across 791 exporters to 180 countries. This indicates a significant domestic demand for zinc formulations, which is met through both domestic production and imports.
The import duty structure for finished pharmaceutical formulations containing zinc under HS Code 30049099 includes:
There are no additional duties such as National Calamity Contingent Duty (NCCD) or Health Cess applicable to these imports.
India sources finished zinc formulations from Poland due to Poland's competitive advantages, including the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. While other suppliers like China, Germany, and the United States also export zinc formulations to India, Poland's share in this market is notable. The specific advantages of Polish products, such as unique formulations or compliance with international quality standards, make them attractive to Indian importers.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished zinc formulations from Poland due to strategic reasons such as access to patented formulations, specialized dosage forms, and technology-licensed products. Poland supplies specific formulations that India does not manufacture domestically, fulfilling therapeutic needs and market demands.
When compared to other origins like China, the European Union, and the United States, Poland offers competitive advantages in terms of price, quality, regulatory compliance, and reliability. Poland's unique advantage lies in its ability to provide high-quality formulations that meet international standards, which is appealing to Indian importers seeking reliable sources.
Indian importers face potential supply chain risks when sourcing finished zinc formulations from Poland, including single-source risk, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal; however, importers should remain vigilant and develop contingency plans to mitigate these risks.
Import license checklist, document requirements, quality testing, and compliance
6.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Zinc suppliers from POLAND to India include Roland Karlinski. The leading supplier is Roland Karlinski with import value of $10 USD across 1 shipments. India imported Zinc worth $10 USD from POLAND in total across 1 shipments.
India imported Zinc worth $10 USD from POLAND across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Zinc sourced from POLAND include MEDICEPT DENTAL INDIA PRIVATE LIMITED. The largest buyer is MEDICEPT DENTAL INDIA PRIVATE LIMITED with $10 in imports across 1 shipments.
The total value of Zinc imports from POLAND to India is $10 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists